Design of Estradiol Loaded PLGA Nanoparticulate Formulations: A Potential Oral Delivery System for Hormone Therapy
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Estradiol (E2), a highly lipophilic molecule with good oral absorption but poor oral bioavailability, was incorporated into poly(lactide-co-glycolide) (PLGA) nanoparticles to improve its oral bioavailability. Nanoparticles were prepared by using polyvinyl alcohol (PVA) or didodecyldimethylammonium bromide (DMAB) as stabilizer, leading to negatively (size 410.9+/-39.4 nm) and positively (size 148.3+/-10.7 nm) charged particles, respectively. Both preparations showed near zero order release in vitro with about 95% drug being released within 45 and 31 days for PVA and DMAB, respectively. In situ intestinal uptake studies in male Sprague-Dawley (SD) rats showed higher uptake of DMAB stabilized nanoparticles. Following oral administration to male SD rats, E2 could be detected in blood for 7 and 2 days from DMAB and PVA stabilized nanoparticles, respectively. Histopathological examination and blood counts indicated the absence of inflammatory response. These data suggest that DMAB stabilized PLGA nanoparticles have great potential as carriers for oral delivery of estradiol.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Particles with a size of 150 nm show a prolonged circulation time and sustained blood levels compared with particles with a size lower than 100 nm or above 200 nm, which may be taken up by the reticulo-endothelial system cells. In comparison, NPs between 100 and 200 nm can escape reticulo-endothelial system uptake [5,43].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [5]
In the citing paper
“Encapsulation of antigens into particle carriers protects against these harsh GI degrading conditions [23], enabling an intestinal uptake of intact antigens and drugs, and the circumvention of the hepatic first-pass metabolism due to protection of the payload by the particle matrix.”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [5]
In the citing paper
“NPs are rapidly internalized mainly by a process that involves receptor-mediated endocytosis, and are then disseminated systemically [5,38].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [5]
In the citing paper
“Both PLGA and PLA are characterized by high biocompatibility and biodegradability, as their degradation products are eliminated via the Krebs cycle, which is why their application in human patients has been approved by the US FDA [3–5].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [5]
In the citing paper
“Additionally, slight differences of NP size have an impact on the availability of encapsulated drugs in the circulation.”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [5]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Jain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Biodegradable nanoparticles for drug delivery and targeting
Hans, M. L., & Lowman, A. M. (2002) · Current Opinion in Solid State and Materials Science · doi:10.1016/s1359-0286(02)00117-1 · Cited by 1,324
Govender, T. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00116-3 · Cited by 1,008
Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 990
The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent
Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J., & Amidon, G. L. (1997) · Pharmaceutical Research · doi:10.1023/a:1012126301290 · Cited by 858 · cited 2×
“Larger particles are known to be readily taken up by the reticuloendothelial system (RES) cells (cells of liver and spleen) (32,29).”
BackgroundPanyam, J., Dali, M. M., Sahoo, S. K., Ma, W., Chakravarthi, S. S., Amidon, G. L., Levy, R. J., & Labhasetwar, V. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00328-6 · Cited by 529
Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa
Lamprecht, A., Schäfer, U., & Lehr, C.-M. (2001) · Pharmaceutical Research · doi:10.1023/a:1011032328064 · Cited by 507
Preparation and characterization of cationic PLGA nanospheres as DNA carriers
Ravi Kumar, M. N. V., Bakowsky, U., & Lehr, C. M. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.08.069 · Cited by 492
Self-citationHormone replacement therapy: Fortnightly review
Barrett-Connor, E. (1998) · BMJ · doi:10.1136/bmj.317.7156.457 · Cited by 403
Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A
El-Shabouri, M. H. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00461-1 · Cited by 392
Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel
Feng, S.-S., Mu, L., Win, K., & Huang, G. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043455909 · Cited by 311
Quintanar-Guerrero, D., Fessi, H., Allémann, E., & Doelker, E. (1996) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(96)04697-2 · Cited by 310
Gutierro, I., Hernández, R. M., Igartua, M., Gascón, A. R., & Pedraz, J. L. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00435-8 · Cited by 292
The effect of physical barriers and properties on the oral absorption of particulates
Norris, D. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00037-4 · Cited by 262
Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics
ALLEMANN, E. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00039-8 · Cited by 257
Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study
Vandervoort, J., & Ludwig, A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00058-3 · Cited by 237
Kumar, M. N. V. R., Sameti, M., Mohapatra, S. S., Kong, X., Lockey, R. F., Bakowsky, U., Lindenblatt, G., Schmidt, C. H., & Lehr, C.-M. (2004) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2004.120 · Cited by 198
Self-citationEnzymatic degradation behavior and mechanism of Poly(lactide-co-glycolide) foams by trypsin
Cai, Q. (2003) · Biomaterials · doi:10.1016/s0142-9612(02)00377-0 · Cited by 161
Controlled release of β-estradiol from PLAGA microparticles:
Birnbaum, D. T., Kosmala, J. D., Henthorn, D. B., & Brannon‐Peppas, L. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00219-9 · Cited by 154
Murakami, H., Kawashimà, Y., Niwa, T., Hino, T., Takeuchi, H., & Kobayashi, M. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(96)04854-5 · Cited by 133
Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties
Arbós, P., Campanero, M. A., Arangoa, M. A., Renedo, M. J., & Irache, J. M. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00066-x · Cited by 129
Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles
Verdun, C., Brasseur, F., Vranckx, H., Couvreur, P., & Roland, M. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf02940287 · Cited by 115
Cationic Poly(lactide-co-glycolide) Nanoparticles as Efficient in vivo Gene Transfection Agents
RaviKumar, M. N. V., Mohapatra, S. S., Kong, X., Jena, P. K., Bakowsky, U., & Lehrd, C.-M. (2004) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2004.130 · Cited by 94
Self-citationNovel Approaches for Oral Delivery of Macromolecules
Fasano, A. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980076h · Cited by 86
Drug Targeting by Surface Cationization
Blau, S., Jubeh, T. T., Haupt, S. M., & Rubinstein, A. (2000) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v17.i5.10 · Cited by 84
Models of breast cancer: quo vadis, animal modeling?
Wagner, K. (2003) · Breast Cancer Research · doi:10.1186/bcr723 · Cited by 81
Transdermal delivery of drugs for the treatment of bone diseases
Ramachandran, C., & Fleisher, D. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00062-4 · Cited by 77
Design of an intravaginal ring for the controlled delivery of 17β-estradiol as its 3-acetate ester
Woolfson, A. D., Elliott, G. R. E., Gilligan, C. A., & Passmore, C. M. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00148-0 · Cited by 70
Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments
Lakshmanaswamy, R., Guzman, R. C., Yang, J., Thórdarson, G., Talamantes, F. J., & Nandi, S. (2003) · Breast Cancer Research · doi:10.1186/bcr734 · Cited by 59
Microdialysis for evaluating the entrapment and release of a lipophilic drug from nanoparticles
Michalowski, C. B., Guterres, S. S., & Costa, T. D. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2004.04.002 · Cited by 56
Clinical Monograph: Hormone Replacement Therapy
Deady, J. (2004) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2004.10.1.33 · Cited by 37
Sandor, M., Harris, J., & Mathiowitz, E. (2002) · Biomaterials · doi:10.1016/s0142-9612(02)00183-7 · Cited by 32
Practical measurement of total and bioavailable estradiol in female macaques
Pazol, K., Kaplan, J. R., Abbott, D. H., Appt, S. E., & Wilson, M. E. (2003) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.10.010 · Cited by 31
Djaković‐Sekulić, T., Ačanski, M., & Perišić-Janjić, N. U. (2002) · Journal of Chromatography B · doi:10.1016/s0378-4347(01)00435-2 · Cited by 28
Ritz, M., Schmidt, P., & Mendelowitsch, A. (2002) · Neurochemical Research · doi:10.1023/a:1021695213099 · Cited by 23
Resetarits, D. E., Cheng, K. C., Bolton, B. A., Prasad, P. N., Shefter, E., & Bates, T. R. (1979) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(79)90054-1 · Cited by 13
Otsuka, M., Uenodan, H., Matsuda, Y., Mogi, T., Ohshima, H., & Makino, K. (2002) · PubMed · Cited by 8
[Uptake of drug-containing nanoparticles in dog catotid and femoral arteries].
Song, C., Zhu, Z., Yang, J., Sun, H., Leng, X., Wu, L., Tang, L., Wang, P., & Levy, R. (2000) · PubMed · Cited by 3
Research works printed but not linked: 4
- J. Deady, 2004, J. Manag. Care Pharm., 10, 544
- C. Song, 2000, Zhongguo Yixue Kexueyuan Xuebao, 22, 440
- M. Otsuka, 2002, Biomed. Mater. Eng., 12, 157
- S. Maassen, 1993, STP Pharma Sci., 3, 11
Cited by
Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach
des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., & Préat, V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.013 · Cited by 1,305
Shaikh, J., Ankola, D. D., Beniwal, V., Singh, D., & Kumar, M. N. V. R. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.02.019 · Cited by 956
Hosseini, S. F., Zandi, M., Rezaei, M., & Farahmandghavi, F. (2013) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2013.02.031 · Cited by 936
Miniemulsion Polymerization and the Structure of Polymer and Hybrid Nanoparticles
Landfester, K. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200900723 · Cited by 772
Wilson, D. S., Dalmasso, G., Wang, L., Sitaraman, S. V., Merlin, D., & Murthy, N. (2010) · Nature Materials · doi:10.1038/nmat2859 · Cited by 747
Metadata
- Authors
- Hariharan, S., Bhardwaj, V., Bala, I., Sitterberg, J., Bakowsky, U., & Ravi Kumar, M. N. V.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- Philipps University of Marburg (DE)
- ORCID
- Venue
- Pharmaceutical Research
- Published
- 2006-01
- Volume
- 23
- Issue
- 1
- Pages
- 184-195
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2148628183
- Cited by
- 257
- References
- 39
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 6 · 2023: 11 · 2022: 16 · 2021: 10 · 2020: 13 · 2019: 19 · 2018: 9 · 2017: 17 · 2016: 16 · 2015: 15 · 2014: 16 · 2013: 14 · 2012: 16
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Royal Society
- Royal Society of Chemistry
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- estradiol, PLGA nanoparticles, oral drug delivery, oral bioavailability, polyvinyl alcohol stabilizer, didodecyldimethylammonium bromide, nanoparticle surface charge, controlled drug release, hormone therapy, nanocarriers
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Chemistry, Pharmaceutical, Drug Compounding, Electrochemistry, Estradiol, Male, Particle Size, Polyglycolic Acid, Polymers, Rats, Sprague-Dawley, Lactic Acid, Nanostructures, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.